Galapagos (Euronext: GLPG) said on Tuesday that its chief financial officer and chief operating officer Thad Huston will ...

US pharma major Bristol Myers Squibb (NYSE: BMY) yesterday disclosed that its Phase III ODYSSEY-HCM trial of Camzyos ...

Austrian drug delivery specialist Cyprumed GmbH and US pharma giant Merck & Co (NYSE: MRK), known as MSD outside of the USA and Canada, have signed a non-exclusive license and option agreement to ...

Privately-held US biotech Attovia Therapeutics, which is developing treatments for immune-mediated diseases with high unmet patient need, today announced the close of a $90 million Series C financing.

Danish pharma major Novo Nordisk says that it has become aware of several hundred units of Ozempic (semaglutide) injection 1 mg distributed outside its authorized supply chain in the USA.

German biotech HepaRegeniX has raised 21.5 million euros ($23 million) in new funding to support the clinical development of its lead candidate, HRX-215, a first-in-class treatment aimed at enhancing ...

Shares in Johnson & Johnson were 1% lower in the early stages of Tuesday’s trading after the US health conglomerate presented its first-quarter 2025 financial results.

Cambridge, USA-based biotech Oak Hill Bio, which is focused on acquiring and developing life-changing rare disease therapeutics, has entered into an exclusive license agreement with Roche (ROG: SIX) ...

New research from consultancy Vital Transformation has shown the effects of US policy the Inflation Reduction Act’s (IRA) drug pricing provisions on biopharmaceutical investment, research and ...

San Francisco, USA-based inflammatory disease biotech Third Harmonic Bio (Nasdaq: THRD) saw its shares rocket almost 40% to $5.09 as the company revealed an orderly exit plan.

German family-owned drug major Boehringer Ingelheim and Cue Biopharma (Nasdaq: CUE) have announced a strategic research collaboration and license agreement to develop and commercialize Cue Biopharma’s ...